BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FB825 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FB825\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06397911-1367@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:FB825: Phase 2 readout est. (NCT06397911)
DESCRIPTION:FB825\, phase 2\, Atopic Dermatitis.\nStudy: Evaluate Efficacy 
 and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-t
 o-Severe Atopic Dermatitis\nEstimated primary completion: 31 May 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/fb825#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06397911
URL:https://assetmemo.bio/drug/fb825#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05008965-1367@assetmemo.bio
DTSTAMP:20261121T004538Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:FB825: Phase 2 readout est. (NCT05008965)
DESCRIPTION:FB825\, phase 2.\nStudy: Evaluate the Efficacy and Safety of FB
 825 in Adult With Allergic Asthma\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fb825#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05008965
URL:https://assetmemo.bio/drug/fb825#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
